Advanced search
Publication Cover
Future Oncology Volume 20, 2024 - Issue 13
Submit an article Journal homepage
938
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan

Hitomi Sanno1 MSD K.K., Tokyo, Kitanomaru Square, 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0009-6190-4998
ORCID Icon,
Kazuko Taniguchi1 MSD K.K., Tokyo, Kitanomaru Square, 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, JapanORCID Iconhttps://orcid.org/0000-0001-7706-0157
ORCID Icon,
Yuya Yoshimoto2 Department of Radiation Oncology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, JapanORCID Iconhttps://orcid.org/0000-0002-4967-6736
ORCID Icon &
Shigehira Saji3 Department of Medical Oncology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, JapanORCID Iconhttps://orcid.org/0000-0002-6732-8030
ORCID Icon
Pages 833-849 | Received 09 Nov 2023, Accepted 16 Jan 2024, Published online: 02 Feb 2024

References

  • Sung H , FerlayJ , SiegelRLet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
  • National Cancer Institute Cancer Information Service . Statistics by Cancer Species—Breast. ( In Japanese). https://ganjoho.jp/reg_stat/statistics/stat/cancer/14_breast.html#anchor3 (Accessed 30January2023).
  • Japanese Breast Cancer Society . Breast Cancer Clinical Practice Guidelines 2022. ( In Japanese). https://jbcs.xsrv.jp/guideline/2022/ (Accessed 30January2023).
  • Kosaka Y , MinataniN , TanakaYet al. Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer. Mol Clin Oncol.9(5), 566–574 (2018).
  • Baser O , WeiW , HenkHJ , TeitelbaumA , XieL. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry. Curr. Med. Res. Opin.28(3), 419–428 (2012).
  • Dent R , TrudeauM , PritchardKIet al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res.13(15 Pt 1), 4429–4434 (2007).
  • Li X , YangJ , PengLet al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res. Treat.161(2), 279–287 (2017).
  • Lin NU , VanderplasA , HughesMEet al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer118(22), 5463–5472 (2012).
  • Brandão M , MoraisS , Lopes-ConceiçãoLet al. Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype. ESMO Open.5(6), e000984 (2020).
  • Chugai Pharmaceutical . TECENTRIQ® Interview Form, revised May 2022 (version 14). ( in Japanese). www.info.pmda.go.jp/go/pack/4291441A1024_1_15/ (Accessed 7December2022).
  • Iwase M , AndoM , AogiKet al. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Res. Treat.180(3), 687–694 (2020).
  • Masuda H , MasudaN , KodamaYet al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother. Pharmacol.67(4), 911–917 (2011).
  • Nakashoji A , MatsuiA , NagayamaA , IwataY , SasaharaM , MurataY. Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Oncol Lett.14(4), 4135–4141 (2017).
  • Yagata H , KajiuraY , YamauchiH. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer.18(3), 165–173 (2011).
  • Iwase H , KurebayashiJ , TsudaHet al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer.17(2), 118–124 (2010).
  • Japanese Breast Cancer Society . Main combination therapies for initial treatment of breast cancer. ( In Japanese). https://jbcs.xsrv.jp/guidline/2018/index/yakubutu/app1/ (Accessed 29November2022).
  • Japan Society of Clinical Oncology . Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolecent, and young adult cancear patients. Breast, CQ2: is delayed chemotherapy tolerable if breast cancer patients want fertility preservation? ( In Japanese). www.jsco-cpg.jp/fertility/guideline/#III_cq02 (Accessed 29November2022).
  • Haiderali A , RhodesWC , GautamSet al. Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancer. Future Oncol.17(29), 3833–3841 (2021).
  • National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 1, 2022. www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed 29November2022).
  • Korde LA , SomerfieldMR , HershmanDL. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. J. Clin. Oncol.40(15), 1696–1698 (2022).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.